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Abstract
Problem: B cells are vital for the normal evolution of pregnancy due to their humoral 
and possible regulatory activities. Our group and others have documented that circu‐
lating B‐cell subsets undergo changes from normal late pregnancy to the postpartum 
period. However, the underlying mechanisms are poorly understood. Therefore, this 
study examined the degree of B‐cell activation in normal pregnancy by analyzing the 
levels of serum markers in healthy pregnant women during the third trimester of 
pregnancy, the day of delivery, and the postpartum period.
Method of study: A prospective study including pregnant and non‐pregnant women 
attending	 routine	care	was	undertaken	at	 a	hospital	 clinic.	 Sociodemographic	and	
clinical data were collected, along with peripheral blood samples. The serum levels of 
soluble CD23 (sCD23), B‐cell‐activating factor (BAFF), kappa (κ) and lambda (λ) free 
light chains (FLC), IgA, IgG, and IgM were quantified.
Results:  Our study included 43 third trimester pregnant and 35 non‐pregnant 
women. In the pregnant women, the median levels of sCD23, BAFF, IgG, and κ FLC 
were significantly higher during the postpartum period than during the third trimes‐
ter of pregnancy. Compared to the non‐pregnant women, the third trimester preg‐
nant women had higher median BAFF levels and lower sCD23, IgA, IgG, and FLC 
levels.
Conclusion: Changes in serum markers of B‐cell kinetics that occur during pregnancy 
often persist into the postpartum period and affect the secretion of immunoglobulins 
from different classes. Further studies are needed to clarify the biological signifi‐
cance of our observations.
K E Y W O R D S
B lymphocytes, B‐cell‐activating factor, biomarkers, female, free light chains, 
immunoglobulins, pregnancy, soluble CD23
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1  | INTRODUCTION
Successful	pregnancy	requires	major	regulation	of	the	maternal	 im‐
mune system without compromising its role in the protection of either 
the mother or fetus.1 B cells play an essential role in pregnancy be‐
cause they are paramount for humoral activity and the production of 
antibodies, which are also implicated in the normal evolution of preg‐
nancy.	Nevertheless,	B	cells	may	cause	obstetric	complications,	such	
as pregnancy loss, preeclampsia, intrauterine growth restriction, still‐
birth, and preterm birth, through the production of autoantibodies.2‐4
We	have	previously	reported	that	peripheral	blood	B‐cell	subsets	
undergo quantitative changes from the third trimester of pregnancy 
to the postpartum period in healthy pregnant women.5‐7 According 
to our study, late pregnancy is accompanied by peripheral blood B‐
cell lymphopenia followed by a recovery of B‐cell levels later during 
the postpartum period.5 Recent studies that have assessed gene ex‐
pression	in	maternal	plasma	and	in	the	placenta	by	RNA	sequencing	
have further confirmed this hypothesis.8,9 Moreover, pregnancy‐as‐
sociated B‐cell lymphopenia has already been described in animal 
models10,11 and humans12‐22 and probably occurs due to hormonal 
influences10,11 and/or cellular migratory mechanisms during the later 
stages of pregnancy.23‐26
Although the biological significance of the suppression of B‐cell 
lymphopoiesis in normal pregnancy is still unclear, this suppres‐
sion may be related to the physiology of maternal‐fetal immune 
tolerance.10
Additional data addressing changes in B‐cell biology during 
pregnancy can be obtained by the analysis of serum markers of 
B‐cell function, such as via measurements of the levels of B‐cell‐
activating factor (BAFF), serum soluble CD23 (sCD23), immuno‐
globulins (Ig), and free light chains (FLC), which are elevated in 
several autoimmune diseases, namely, rheumatoid arthritis,27,28 
Sjogren	 syndrome,29	 and	 systemic	 lupus	 erythematosus	 (SLE).30 
Additionally, elevated serum concentrations of BAFF have been 
described in B‐cell malignancies and in primary and acquired im‐
munodeficiencies,31‐34 although whether these increases are cor‐
related with qualitative or quantitative changes in the circulating 
B‐cell compartment remains unknown. Higher BAFF levels may be 
a physiological response to ensure the survival of transitional B 
cells and to support the expansion of a growing B‐cell compart‐
ment.35 In healthy adults, soluble BAFF levels are very low, sug‐
gesting that the amounts of BAFF produced are the quantities that 
are necessary to provide sufficient survival signals to maintain and 
limit the size of the steady‐state B‐cell pool.36	Strikingly,	Muzio	et	
al11 showed that the numbers of pre‐/pro‐ and immature B cells 
were progressively diminished during pregnancy in the bone mar‐
row of pregnant mice, leading to a reduction in B‐cell influx into 
the blood and spleen. Correspondingly, lower BAFF levels were ob‐
served	in	the	sera	of	pregnant	mice.	In	addition,	Bienertova‐Vasku	
et al37 recently demonstrated that the BAFF levels in circulating 
human maternal blood were significantly higher in women with 
normal pregnancies than in pregnant women with preeclampsia.
CD23 is expressed on earliest B cells exiting the bone marrow 
while the post‐germinal center and other memory B cells are negative 
for this marker.38 Following B‐cell activation, as the surface expres‐
sion	of	CD27	induces	cleavage	of	CD23,	sCD23	levels	can	be	used	
as a measurement of B‐cell turnover from naïve to memory B cells.39 
The soluble factor sCD23 is stable for 12‐24 hours in serum and has 
been used by us and others as a surrogate measure of naïve B‐cell 
activation or differentiation.28 Excess FLC are released into the circu‐
lation by terminally differentiated B cells, antibody‐producing cells. 
The evaluation of serum FLC levels has been shown to be useful for 
monitoring the activity of autoimmune diseases such as lupus,29,30 
and serum FLC levels may even be superior to the usual biomarkers 
such	as	complement,	double‐stranded	DNA,	and	serum	Ig.30
Little is known about whether markers of B‐cell activation and 
differentiation change during normal human pregnancy. Therefore, 
the aim of this study was to explore the relationship between the 
levels of serum markers of B‐cell activation and B‐cell maturation 
into memory and Ig‐secreting cells during late pregnancy and the 
postpartum	 period	 of	 healthy	 pregnant	 women.	 Specifically,	 this	
study uses quantitative data from enzyme‐linked immunosorbent 
assays	 (ELISAs)	 to	 determine	 the	 extents	 to	 which	 the	 levels	 of	
serum sCD23, BAFF, serum kappa (κ) and lambda (λ) FLC, IgA, IgG, 
and IgM change from the third trimester of pregnancy and the day 
of delivery to the postpartum period and compare these values to 
those of non‐pregnant women. This report presents one of the first 
investigations of the degree of B‐cell activation in normal pregnancy. 
This characterization is important for our increased understanding 
of the resumption of autoimmune responses and their associations 
with B‐cell kinetics following delivery and the postpartum period.
2  | MATERIALS AND METHODS
2.1 | Study design and participants
This is a prospective observational study conducted under the scope 
of our project on the characterization of the circulating B‐cell popu‐
lations of healthy non‐pregnant and pregnant women from the third 
trimester of pregnancy to the postpartum period.5
All	women	were	enrolled	 in	 the	 study	between	 July	2013	and	
March 2014 at Hospital CUF Descobertas in Lisbon (Portugal). 
Consecutive nonlaboring pregnant women who were receiving rou‐
tine prenatal care at a hospital outpatient clinic during the third tri‐
mester of pregnancy were eligible for this prospective study. Third 
trimester pregnant women were included in the study if they had 
no prior pregnancy complications and if their fetuses exhibited ap‐
propriate growth, as assessed by uterine fundal height and by an 
ultrasound performed after 28 weeks of gestation. Exclusion cri‐
teria for third trimester pregnant women were multiple pregnancy, 
ongoing pregnancy complications (including preeclampsia), delivery 
of	a	premature	infant	(born	before	37	weeks	of	gestation),	induced	
labor, signs of infection, or prenatal use of any medication other than 
vitamins and iron supplementation.
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As a control group, we recruited consecutive healthy non‐preg‐
nant women who were attending routine annual well‐woman ex‐
aminations at the hospital outpatient clinic. Exclusion criteria for 
non‐pregnant women were the use of hormonal oral contraceptives, 
as these drugs may affect the levels of peripheral blood lymphocyte 
subsets.40 Furthermore, the following exclusion criteria were applied 
for both pregnant and non‐pregnant women: diabetes; hypertension; 
autoimmune	diseases;	vascular	diseases;	HIV,	syphilis,	or	hepatitis	B	
or C infection; or smoking within 6 months prior to study inclusion.
From each pregnant woman, we collected peripheral blood sam‐
ples during three planned clinic visits: (a) during the third trimester of 
pregnancy; (b) on the day of delivery, within 15 minutes of placental 
expulsion and oxytocin administration; and (c) during the postpar‐
tum period, at least six weeks after delivery. From each non‐pregnant 
woman, we collected a single peripheral blood sample at one planned 
clinic visit during the follicular phase of her menstrual cycle because 
the luteal phase may change the levels of peripheral blood lympho‐
cyte subsets in a manner that is similar to that of pregnancy.41
The present study quantified the serum levels of the follow‐
ing B‐cell markers: sCD23, which is enzymatically cleaved and re‐
leased from naïve B cells following activation; BAFF (also known 
as	 TNFSF13B	 or	 BLyS	 protein);	 κ FLC and λ FLC, as measures of 
plasmablast activity; and IgA, IgG, and IgM.
All procedures performed in our study involving human partic‐
ipants were conducted in accordance with the ethical standards of 
the institutional research committee and with the 1964 Declaration 
of Helsinki and its later amendments or comparable ethical stan‐
dards. This article does not contain any studies with animals per‐
formed by any of the authors. The hospital's Ethics Committee 
approved our study protocol, and all participants provided their 
signed informed consent prior to their inclusion in the study.
2.2 | Baseline characteristics
Baseline data collected for all study participants included age, ances‐
try, body mass index, blood pressure, and obstetric history. Data col‐
lected for the pregnant women included gestational age at the first 
planned visit (third trimester of pregnancy) and on the day of deliv‐
ery; usage of obstetrical anesthesia and/or analgesia; and mode of 
delivery. Data collected for the newborns included sex, birth weight, 
and 1‐ and 5‐minutes APGAR scores.
2.3 | Sample collection and measurements
Peripheral blood samples were collected into tubes without any an‐
ticoagulant agent and were centrifuged after coagulum retraction. 
Serum	was	separated,	aliquoted,	and	stored	at	−20°C	until	 further	
analysis. The serum concentrations of human CD23/FcεRII (pg/mL) 
and	 human	 BAFF/BLyS/TNFSF13B	 (pg/mL)	 were	 quantified	 using	
the	Quantikine®	ELISA	commercial	kits	(R&D	Systems	Europe	Ltd,	
Abingdon, UK) according to the manufacturer's instructions. The 
mean minimum detectable doses of these kits were 3.18 pg/mL 
and 2.68 pg/mL for human CD23/FcεRII (pg/mL) and human BAFF/
BLyS/TNFSF13B,	respectively.
The total IgA, IgG, and IgM serum concentrations (g/L) were de‐
termined	using	 in‐house	nephelometry	by	Binding	Site	Group	Ltd.	
(Birmingham, UK).
The human κ FLC and λ FLC serum concentrations (mg/L) were 
analyzed	 using	 Freelite,	 a	 commercial	 ELISA	 kit	 (Binding	 Site),	 ac‐
cording to the manufacturer's instructions. The limits of detection 
for these kits were 6 and 5 μg/L for human κ FLC and λ FLC, respec‐
tively. The κ/λ FLC ratio was also calculated and used as an indicator 
of clonal expansion.
2.4 | Statistical analysis
The characteristics of the study participants and levels of the 
serum markers of immune activation were summarized using de‐
scriptive statistics. The normality of the data was assessed using 
TA B L E  1   Baseline characteristics of non‐pregnant women and 
of third trimester pregnant women and their newborns
Characteristics
non‐pregnant 
(n = 35) Pregnant (n = 43)
Age, median (minimum‐
maximum), y
35.0 (20‐40) 32.0 (25‐41)*
Body mass index, mean 
(SD),	kg/m2
21.5 (2.8) 26.2 (2.8)
Blood	pressure,	mean	(SD),	mm	Hg
Systolic 119.8 (10.5) 115.7	(9.3)
Diastolic 74.7	(7.4) 67.4	(7.4)
Ancestry, no. (%)
European 35 (100) 42	(97.8)
African 0 1 (2.2)
Parity, no. (%)
Nulliparous 5 (14.3) 24 (55.8)***
Primiparous 14 (40.0) 18 (41.9)
Multiparous 16	(45.7) 1 (2.3)
Gestational period, median (minimum‐maximum), wk
Third trimester of 
pregnancy
33.0 (31‐35)
Day of delivery 39.0	(37‐41)
Mode of delivery, no. (%)
Vaginal 18 (41.8)
Cesarean 25 (58.2)
Newborns
Male, no. (%) 22 (51.0)
Birth	weight,	mean	(SD),	g 3265.0 (393.5)
APGAR score, median (minimum‐maximum)
1‐min 9 (6‐10)
5‐min 10 (9‐10)
SD,	standard	deviation.
*p‐value <0.05; 
***p‐value <0.001. 
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the	Shapiro‐Wilk	test.	Continuous	variables	are	presented	as	the	
mean (standard deviation) or median (minimum‐maximum), as ap‐
plicable.	Two	independent	groups	were	assessed	using	Student's	
t‐test	 or	 the	Wilcoxon	 rank‐sum	 test,	 as	 applicable.	 Paired	data	
were	 compared	 using	 paired	 Student's	 t‐tests	 or	 the	Wilcoxon	
signed‐rank test, as appropriate. Comparisons between more 
than two groups were performed using analysis of variance 
(ANOVA),	 the	 Kruskal‐Wallis	 test,	 or	 the	 Friedman	 test,	 as	 ap‐
plicable.	 For	 the	 assessment	 of	 correlations,	 Spearman	 correla‐
tion coefficients were calculated. P‐values for all comparisons 
were adjusted for multiplicity using the Benjamini and Yekutieli 
method.42 Categorical samples were expressed as numbers and 
percentages	 and	 compared	 using	 Fisher's	 exact	 test.	 Statistical	
significance was concluded at the level of 0.05. This was an ex‐
ploratory study in which no calculation was performed to deter‐
mine the sample size. All data analyses were conducted with R 
Core	Team,	Vienna,	Austria.
3  | RESULTS
3.1 | Baseline characteristics
During the eight‐month study period, 48 third trimester pregnant 
women were enrolled in the study. Five pregnant women were 
excluded from further analysis due to the delivery of a premature 
infant (n = 3), delivery outside the study site (n = 1), or technical dif‐
ficulties (n = 1). Only the data of the remaining 43 third trimester 
pregnant women were included in our analysis. In addition, 35 non‐
pregnant women were included in the study.
The baseline characteristics of the non‐pregnant women and 
of the third trimester pregnant women and their newborns are 
shown in Table 1. Briefly, the median age of the third trimester 
pregnant women was 32.0 years (25‐41), and 55.8% were nullip‐
arous. Their mean body mass index was 26.2 (2.8) kg/m2, their 
mean	 systolic	 blood	 pressure	 was	 115.7	 (9.3)	mm	Hg,	 and	 their	
mean	diastolic	blood	pressure	was	67.4	(7.4)	mm	Hg.	The	median	
gestational	ages	were	33.0	(31‐35)	weeks	and	39.0	(37‐41)	weeks	
in the third trimester of pregnancy and on the day of delivery, 
respectively. The mean infant birth weight for 43 newborns was 
3265.0 (393.5) g. All pregnant women received obstetrical anes‐
thesia and/or analgesia regardless of the mode of delivery, and 
no general anesthesia was administered. In general, the pregnant 
women were discharged from the hospital 2 days after a vaginal 
delivery or 3 days after a cesarean section. The planned clinic 
visits during the postpartum period occurred at a median time of 
45 (range 41‐58) days after delivery. Regarding the non‐pregnant 
women, their median age was 35.0 (range 20‐40) years, and 40% 
were primiparous. Their mean body mass index was 21.5 (2.8) kg/
m2, their mean systolic blood pressure was 119.8 (10.5) mm Hg, 
and	their	mean	diastolic	blood	pressure	was	74.7	(7.4)	mm	Hg.	For	
the non‐pregnant women, the median time since their last preg‐
nancy was 169 (range 23‐449) weeks (including live birth or an 
interrupted pregnancy).
The third trimester pregnant women were significantly younger 
(P = 0.016) and included significantly more nulliparous women 
(P	<	0.001)	than	the	non‐pregnant	women.	Nevertheless,	no	significant	
correlations were found between age and the levels of the studied B‐
cell markers, namely, sCD23, BAFF, κ FLC, λ FLC, IgA, IgG, and IgM, for 
either the pregnant women or non‐pregnant women (data not shown). 
Similarly,	no	significant	differences	were	found	in	the	measured	serum	
parameters between the different parities, within the group of third tri‐
mester pregnant women or within the group of non‐pregnant women 
(see	Table	S1),	or	between	vaginal	compared	 to	cesarean	delivery	at	
third trimester, day of delivery, or postpartum period in the group of 
third	trimester	pregnant	women	(see	Table	S2).
3.2 | BAFF levels are higher in third trimester 
pregnant women than in non‐pregnant women
We	have	found	that	 the	median	BAFF	 levels	were	significantly	 in‐
creased in pregnant women at all study visits compared to non‐preg‐
nant women (third trimester of pregnancy, P < 0.001; day of delivery, 
F I G U R E  1   Box (median ± interquartile 
ranges) and whiskers (10th and 90th 
percentiles) of the serum BAFF (A) and 
sCD23 (B) levels in the peripheral blood 
of non‐pregnant women (n = 35) and 
pregnant women (n = 43) during the 
third trimester of pregnancy, on the day 
of delivery within 15 min after placental 
expulsion, and during the postpartum 
period at least 6 wk after delivery. The 
gray area indicates the range of normal 
values. Differences between groups were 
tested	using	analysis	of	variance	(ANOVA)	
or the Friedman test. *P‐value <0.05; **P‐
value <0.01; ***P‐value <0.001
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P < 0.001; postpartum period, P < 0.001; Figure 1A). In the third tri‐
mester pregnant women, BAFF levels were significantly higher on 
the day of delivery (P	=	0.007)	 and	 during	 the	 postpartum	 period	
(P = 0.005) than during the third trimester of pregnancy.
We	did	not	find	significant	correlations	between	the	serum	BAFF	
levels and the absolute or relative circulating B‐cell levels (see Table 
S3).
3.3 | Soluble CD23 levels increase during the 
postpartum period
The median sCD23 serum levels varied throughout the third trimes‐
ter of pregnancy to the postpartum period in the pregnant women 
and between the third trimester pregnant women and non‐pregnant 
women	(Figure	1B).	Specifically,	the	sCD23	levels	were	significantly	
lower in the pregnant women during the third trimester of preg‐
nancy than in the non‐pregnant women (P = 0.002). Moreover, the 
sCD23 levels increased significantly in the pregnant women during 
the postpartum period compared to the third trimester of pregnancy 
(P = 0.004) and to the day of delivery (P = 0.005).
3.4 | IgA levels are lower in third trimester pregnant 
women and decrease on the day of delivery
The median IgA levels were significantly lower in the third trimester 
pregnant women, regardless of the timing of the clinic visit, than in 
the non‐pregnant women (third trimester of pregnancy, P < 0.001; 
day of delivery, P < 0.001; postpartum period, P = 0.009; Figure 2A). 
In addition, the median IgA levels decreased significantly on the day 
of delivery compared to the third trimester of pregnancy (P	=	0.007)	
and increased significantly from the day of delivery to the postpar‐
tum period (P < 0.001).
3.5 | IgG levels are lower in third trimester pregnant 
women and often below the normal range at delivery
The median IgG levels showed a similar tendency to that of the IgA 
levels, being significantly lower in the pregnant women during all 
visits than in the non‐pregnant women (Figure 2B; P < 0.001). In the 
third trimester pregnant women, the lowest median IgG levels were 
detected on the day of delivery and increased significantly during the 
postpartum period compared to both the day of delivery (P < 0.001) 
and the third trimester of pregnancy (P < 0.001). In contrast to the 
changes observed in the IgA levels, the IgG levels were significantly 
higher during the postpartum period than during the third trimester. 
Both during the third trimester and, particularly, at delivery, the IgG 
levels were often below the normal range.
3.6 | IgM levels are not different between 
pregnant and non‐pregnant women
There were no significant differences in the median IgM levels be‐
tween the pregnant and non‐pregnant women (Figure 2C). Moreover, 
in the third trimester pregnant women, the median IgM levels only 
showed a slight but significant increase during the postpartum pe‐
riod compared to the day of delivery (P < 0.001).
F I G U R E  2   Box (median ± interquartile ranges) and whiskers (10th and 90th percentiles) of the total serum levels of (A) IgA, (B) IgG, and 
(C) IgM in the peripheral blood of non‐pregnant women (n = 35) and pregnant women (n = 43) during the third trimester of pregnancy, on the 
day of delivery within 15 min after placental expulsion, and during the postpartum period at least 6 wk after delivery. The gray area indicates 
the range of normal values. There was one missing value for IgA in the pregnant women group. Differences between groups were tested 
using	analysis	of	variance	(ANOVA)	or	the	Friedman	test.	*P‐value <0.05; **P‐value <0.01; ***P‐value <0.001
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3.7 | The κ/λ FLC ratio increases during the 
postpartum period
The serum FLC levels followed the same pattern as that of the meas‐
ured class‐switched Ig (IgA and IgG) levels, with the median levels of 
both κ and λ FLC being significantly higher during the postpartum 
period than on the day of delivery (Figure 3A,B). The levels of κ FLC 
recovered during the postpartum period and were not significantly 
different from those of the non‐pregnant women, whereas the levels 
of λ FLC remained low. This was reflected by the changes in the κ/λ 
FLC ratio (Figure 3C).
4  | DISCUSSION
In our previous study, we found that the levels of some peripheral 
blood B‐cell subsets significantly vary throughout the third trimester 
of pregnancy until the postpartum period.5 Thus, we hypothesized 
that these changes might be accompanied by variations in mark‐
ers of immune activation, namely, sCD23 and BAFF, given their re‐
ported relationship with B‐cell differentiation and transitional B‐cell 
survival, respectively. However, the literature is scarce regarding 
the expression of markers of B‐cell activation during normal human 
pregnancy. Therefore, in the present study, we aimed to address this 
problem by quantifying the serum levels of sCD23, BAFF, κ and λ 
FLC, IgA, IgG, and IgM in the peripheral blood of healthy pregnant 
women (third trimester of pregnancy, the day of delivery, and post‐
partum period) and non‐pregnant women.
Soluble	 CD23	 levels	 in	 the	 peripheral	 blood	 have	 been	 previ‐
ously explored in human pregnancy, comparing women with normal 
gestations (only during the first trimester) to women who experi‐
enced spontaneous abortions, but there was no difference between 
the two groups.43	We	found	that	the	serum	sCD23	levels	were	sig‐
nificantly lower in the pregnant women during the third trimester of 
pregnancy and increased during the postpartum period. Considering 
that the presence of sCD23 fragments in the circulation is thought to 
depend on the turnover from naïve to memory B cells, our findings 
are consistent with our previous report,5 as we identified a relative 
increase in naïve B cells in the third trimester of pregnancy (ie, at 
a time of lower sCD23 levels). Moreover, the rise in sCD23 levels 
during the postpartum period suggests the resumption of B‐cell dif‐
ferentiation into memory B cells, also supported by our previous re‐
sults.5 Interestingly, in patients with rheumatoid arthritis undergoing 
rituximab therapy, we (ML and GC) have previously found that rises 
in sCD23 levels were highly associated with relapse and coincided 
with the increased production of IgM rheumatoid factor and serum 
FLC release.28 Elevated concentrations of these fragments have also 
been frequently associated with inflammatory or lymphoprolifera‐
tive disorders.44,45
Another finding was that the BAFF levels were significantly 
higher in the third trimester pregnant women than in the non‐preg‐
nant women but remained largely within the normal limits. In ad‐
dition, in the pregnant women, the BAFF levels were significantly 
higher on the day of delivery and during the postpartum period than 
during the third trimester of pregnancy. These results reflect those 
of Lundell et al,46 who found that the BAFF levels in maternal plasma 
were higher at 30 days after delivery than at 19 days before giving 
birth.	 Nevertheless,	 the	 mechanisms	 that	 regulate	 the	 circulating	
levels of BAFF are not well understood in humans. This outcome is 
contrary to that reported by Muzzio et al,11 who showed that BAFF 
F I G U R E  3   Box (median ± interquartile ranges) and whiskers (10th and 90th percentiles) of the (A) κ FLC levels, (B) λ FLC levels, (C) and 
κ/λ FLC ratio in the peripheral blood of non‐pregnant women (n = 35) and pregnant women (n = 43) during the third trimester of pregnancy, 
on the day of delivery within 15 min after placental expulsion, and during the postpartum period at least 6 wk after delivery. The gray area 
indicates	the	range	of	normal	values.	Differences	between	groups	were	tested	using	analysis	of	variance	(ANOVA)	or	the	Friedman	test.	*P‐
value <0.05; **P‐value <0.01; ***P‐value <0.001
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levels were decreased in the sera of pregnant mice; however, this 
discrepancy may be due to the different dependencies of human and 
murine B cells on BAFF signaling.
Several	factors	can	explain	our	observation.	First,	BAFF	is	essen‐
tial for B‐cell survival and the differentiation of immature transitional 
B cells into mature naïve cells, and BAFF is an important immune reg‐
ulator that has been reported to be secreted by the placenta.47,48 A 
previous study demonstrated that BAFF exhibits higher expression 
in the trophoblasts and decidua of normal early pregnant women 
than in the tissues of recurrent spontaneous abortion patients,49 
confirming that BAFF may be an essential element in the implanta‐
tion of the embryo and maintenance of pregnancy. In addition, find‐
ings from a recent study have suggested that decidual stromal cells, 
stimulated	with	interferon	(IFN)‐γ	and	IFN‐α, are a cellular source of 
BAFF for the B cells present in the decidua, and this can be of impor‐
tance for local B‐cell homeostasis during pregnancy.50 Prior studies 
have observed an in vivo correlation between BAFF levels and B‐
cell numbers in patients with rheumatoid arthritis receiving B‐cell 
depletion therapy or who have primary antibody deficiencies.28,36 
Following B‐cell depletion, progressively increasing levels of serum 
BAFF may signify an incremental decrease in the total B‐cell pool, as 
in the context of immunodeficiency, peripheral B‐cell numbers and 
the expression of BAFF receptors have been shown to be inversely 
proportional to the concentration of serum BAFF.36
We	 have	 previously	 reported	 that	 compared	 to	 non‐pregnant	
women, a normal healthy pregnancy between the third trimester 
and delivery is associated with a decreased circulating B‐cell com‐
partment that is richer in naïve B cells and poorer in more differenti‐
ated subsets, such as memory cells and plasmablasts.5 The biological 
consequences of this B lymphopenia in normal pregnancy are un‐
certain but probably related to the physiology of immune tolerance. 
Nevertheless,	 in	 the	 present	 study,	 the	 serum	BAFF	 levels,	which	
are usually positively correlated with plasmablast generation,51 
were increased in the healthy third trimester pregnant women. The 
serum BAFF levels in the group of non‐pregnant women evaluated 
here were similar to those previously reported in non‐pregnant non‐
obese women in another study.52 Therefore, the cause‐effect rela‐
tionship between BAFF levels and B‐cell subsets during pregnancy 
remains to be elucidated.
Interestingly, recent studies have shown that hormones such as 
estrogens can modulate the expression of BAFF.53,54 Additionally, 
pregnancy hormones have also an impact in circulating B cells, which 
seems to suggest that the hormone milieu of pregnancy may induce 
B‐cell lymphopenia, thus the relative availability of BAFF receptors 
will also be limited, which may lead to an increase in serum BAFF 
levels. Therefore, increased levels of serum BAFF might be an ef‐
fect of B lymphopenia in normal pregnancy. However, in the pu‐
erperium, B cells are known to recover their circulating levels, and 
still, we observed increased levels of BAFF, even when compared 
to the third trimester. This suggests other regulatory mechanisms 
in the regulation of this molecule. Eventually, BAFF receptors may 
suffer a modulation in the postpartum as observed in autoimmune 
conditions.55 Additionally, the hormonal milieu significantly changes 
after labor, and it may also interfere with the regulation of BAFF 
pathways.	Nevertheless,	our	results	showing	increased	BAFF	levels	
in the maternal serum on the day of delivery and during the postpar‐
tum period can represent a strong B‐cell maturation boost for the 
mother giving birth, as part of a compensatory mechanism that acts 
on the B‐cell compartment to maximize the maternal‐fetal defense 
capacity. In this context, BAFF might contribute to the increase in 
and maturation of B cells in the mother for recovery after B‐cell 
lymphopenia, and this can also explain the higher serum levels of IgG 
and IgM that we observed during the postpartum period. However, 
caution is due here because increased levels of serum BAFF have 
been associated with an amplified B‐cell response with consequent 
autoimmunity33 and may eventually interfere with the course of 
pregnancy in immunocompromised women or in those with auto‐
immune diseases. BAFF levels in maternal peripheral blood have 
been explored in preeclamptic pregnancies in a few studies; how‐
ever, the results have been variable, with some reports showing no 
changes2 and others showing a significant decrease37 in serum BAFF 
in women with preeclampsia comparing with normotensive pregnant 
women.	Studies	with	larger	sample	sizes	may	be	required	to	further	
investigate if BAFF can be a possible biomarker for preeclampsia.
The current study found that the κ/λ FLC ratio increases during 
the postpartum period, which can be related to a higher activity of 
the adaptive immune system. This finding is an indicator of B‐cell 
activation occurring after the systemic immunological reaction asso‐
ciated with childbirth. In addition, the κ/λ FLC ratio provides a sen‐
sitive numerical indicator of clonality.56 Thus, its increase suggests 
that polyclonal hypergammaglobulinemia occurs during the postpar‐
tum period and may be caused by an inflammatory state.
Regarding whether there is variation in the serum levels of Ig, 
we found that IgA levels were lower in the third trimester pregnant 
women than in the non‐pregnant women and decreased further on 
the day of delivery; the IgG levels were lower in the third trimester 
pregnant women at all times of assessment, failing to recover by the 
postpartum period. The IgM levels were not different between the 
pregnant and non‐pregnant women (showing a significant increase 
during the postpartum period compared to on the day of delivery). 
The major Ig in peripheral blood have been investigated in normal 
human pregnancy and during the postpartum period, but the results 
have been highly variable.57‐60 Recently, Ziegler et al61 addressed 
the immunoglobulin profile along pregnancy. Though our results 
are partially in line with this study, for IgM and even IgA, our results 
are	mostly	discrepant	in	what	concerns	IgG.	We	found	an	important	
decrease in IgG during the third trimester, but Ziegler et al,61 which 
evaluated IgG subclasses instead, showed that pregnancy interferes 
differentially with each IgG subclass and that IgG1 is always increased 
in pregnant women compared to non‐pregnant. This inconsistency 
can be attributed to differences in study design, as some studies did 
not include the postpartum period and not all of the women in other 
studies had samples for all time points. Other likely causes include 
differences in laboratory methodologies, sample size, gestational 
age,	ethnicity,	environments,	and	ecosystems.	Second,	although	the	
levels of most Ig remain unchanged during pregnancy, reductions in 
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the levels of IgA and IgG have been reported by other authors.58‐60 
These falls during pregnancy may be due to hemodilution, the leaking 
of IgG through urine, the transfer of IgG from mother to fetus across 
the placenta during the third trimester, or the pregnancy‐associated 
milieu of hormones, especially steroid hormones, which have effects 
on protein synthesis.59,62 Moreover, the levels of both IgA and IgG 
were lower in the third trimester pregnant women, suggesting that 
IgM precursors may not predominate in circulation during late preg‐
nancy or on the day of delivery. Finally, the increase in both serum 
Ig levels and the κ/λ FLC ratio during the postpartum period can be 
explained by an expansion of specific B cells into Ig‐secreting cells.
In general, therefore, it seems that a reinstatement of an anti‐
inflammatory state occurs after delivery, suggesting that there is a 
qualitative immunological dynamic change in pregnant women that is 
closely associated with changes in the serum levels of sCD23, BAFF, 
FLC, and IgG. This study supports evidence from our previous report 
regarding the quantitative changes in the peripheral B‐cell compart‐
ment during the third trimester to the postpartum period.5 One of 
the issues that emerges from these findings is the need to carefully 
clarify the impact of pregnancy‐associated changes in the B‐cell 
compartment on humoral immune function, as the use of maternal 
immunization to protect the health of the pregnant woman, her fetus, 
and the infant has increased over the past decade. Policy changes for 
vaccines aimed at protecting both mothers and their infants during 
the first months of life have occurred, and many health authorities 
are now recommending immunizations during pregnancy.63‐65 These 
new strategies have been reinforced by a recent study demonstrating 
that tetanus, diphtheria, and pertussis vaccination during pregnancy 
increases antibody titers against diphtheria and pertussis, which 
may prevent neonatal pertussis infection.66 Further immunological 
insights can be useful for the improvement of maternal vaccination 
programs to increase their safety and efficiency.
This study has several strengths to be highlighted. First, to ob‐
tain a homogenous sample and reduce potential bias, we only in‐
cluded women with normal singleton pregnancies who delivered 
between	37	and	41	weeks	of	gestation.	Moreover,	this	was	a	pro‐
spective study, with all clinical monitoring (including deliveries) and 
laboratory tests performed by the same research team and under 
the	same	protocol.	Second,	all	the	women	contributed	samples	at	all	
time points, namely, during the third trimester, on the delivery day, 
and during the postpartum period. In addition, we also accounted 
for the phase of the menstrual cycle during which the samples were 
collected from the non‐pregnant women. However, due to its obser‐
vational	nature,	our	study	has	some	 limitations.	We	consecutively	
included all patients who were followed at the outpatient clinic and 
fulfilled the eligibility criteria for which no sample size calculation 
was carried out. However, even with the small sample size, our re‐
sults clearly showed significant differences between the studied 
markers.	 Nevertheless,	 caution	 must	 be	 applied,	 as	 the	 findings	
might not be generalizable to the broader population. Additional 
prospective studies should be performed using larger sample sizes 
and samples from additional time points, such as during the first and 
second trimesters of pregnancy, and should monitor women prior to 
becoming pregnant through the postpartum period. Future research 
should also compare immune cell subsets in the peripheral blood 
and decidua at delivery from the same healthy pregnant women.
In conclusion, to our knowledge, this is the first study to report 
increases in several markers of B‐cell activation during pregnancy, 
namely, BAFF, and during the postpartum period, namely, sCD23 
and the κ/λ FLC ratio. The most obvious finding to emerge from this 
study is that B‐cell activation is an immunological event in pregnancy 
that continues into the postpartum period and affects the secretion 
of Ig molecules from several classes. This study provides important 
insights into the role of B lymphocytes in the immunomodulation of 
normal pregnancy and may help explain the increased susceptibility 
to infection seen during pregnancy.67,68 Another theoretical implica‐
tion of this study is that the role of the placenta as an immunological 
organ may be important for further investigation in the context of 
autoimmune	diseases	such	as	SLE,	as	there	are	reports69,70 showing 
an	increased	rate	of	SLE	flares	during	pregnancy,	and	other	adverse	
obstetric outcomes such as pregnancy loss, fetal growth restric‐
tion, preeclampsia, and preterm birth. Likewise, the occurrence of 
autoimmune diseases during the postpartum period is not uncom‐
mon.71,72 Further prospective and functional studies are mandatory 
to clarify the importance of our observations.
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